AskVantage

Biotech and enhanced humans

DeepMind AI Alphafold 3 finally masters all lifes molecules

AI is slowly starting to understand how life "works" and how to create and manipulate lifes molecules, including DNA, to create new drug treatments, organisms, proteins, and even humans ...

Key takeaways

  • Considering that there are over 200 million known proteins across all lifeforms – and, so far, only 170,000 protein structures have been identified – it made sense to co-opt AI to speed up the process.
  • To achieve these advanced capabilities, AlphaFold 3 was trained on global molecular structural data held within the Protein Data Bank.
  • AlphaFold 3 is available via the AlphaFold Server, which includes a database of 200 million protein structures.
Cite or link to this article

Griffin, M. (2024) 'DeepMind AI Alphafold 3 finally masters all lifes molecules', 311 Institute, 19 June. Available at: https://www.311institute.com/deepmind-ai-alphafold-3-finally-masters-all-lifes-molecules/ (Accessed: 1 October 2026).

Google DeepMind's groundbreaking new Artificial Intelligence (AI) AlphaFold predicts not only the structure of proteins, ligands, DNA, RNA and "all of life's molecules," but also how they'll interact, and it promises a radical, revolutionary acceleration in many fields of science.

Proteins are one of nature's most incredible and versatile inventions. These essential building blocks of life catalyse virtually every chemical reaction in the body, regulate gene expression and the immune system, make up the major structural elements of all cells, and form the major components of muscle.

But why’s this AI called ‘AlphaFold’? Proteins are chains of amino acids that fold spontaneously to form a 3D structure crucial to the protein’s biological function. You can look at their components and sequences on paper, but if you don't know what 3D shape they fold up into, you can't predict what they'll do, or how they'll interact with other molecules.

Various human-operated experimental techniques have been used to determine protein structures, but they’re time-consuming and expensive. Considering that there are over 200 million known proteins across all lifeforms – and, so far, only 170,000 protein structures have been identified – it made sense to co-opt AI to speed up the process. But, until AlphaFold, programs haven’t been able to predict protein structures in a way that’s as accurate as human-based experimental techniques.

AlphaFold 2, released in 2021, was a game-changing breakthrough, predicting 3-D structures for nearly every protein in the human body and enabling all sorts of cutting-edge science. In less than three years, it's been used by researchers worldwide to accelerate discoveries in cancer treatment, malaria vaccines, the creation of plastic-eating enzymes, and countless others – the Alphafold 2 paper currently lists more than 14,000 citations.

So, how is AlphaFold 3 an improvement? Well, the newest version moves beyond just predicting the structure and interactions of proteins to include everything from multiple proteins to DNA, RNA, and small-molecule ligands. (Most drugs are ligands that bind to proteins to change how they interact in human health and disease.)

Check out the new era in medicine

This makes it an absolutely unprecedented resource for simulating how specific proteins in the body will interact with specific drug molecules.

The video above gives you an idea of the structure that AlphaFold 3 generates. It shows its structural prediction for a spike protein (blue) of a common cold virus as it interacts with antibodies (turquoise) and simple sugars (yellow). You can see how accurately AlphaFold 3’s model matches the protein’s true structure, which is underlaid in gray.

To achieve these advanced capabilities, AlphaFold 3 was trained on global molecular structural data held within the Protein Data Bank. Deepmind says it can process over 99% of all known biomolecular complexes in that database. In addition, its Evoformer module, the architecture that allowed AlphaFold 2 to perform like it did, was improved.

This is how the AlphaFold system works in very, very basic terms. (Thanks to the University of Oxford’s Protein Informatics Group for its easier-to-understand explanation.) It takes the amino acid sequence that’s input, searches databases for similar sequences already identified in other living organisms, extracts all of the relevant information using a transformer (that’s the Evoformer), and passes that information on to a neural network that produces a 3D structure – a long list of coordinates representing the position of each atom of the protein, including side chains.

What the new-and-improved Evoformer does is assemble its structural predictions using a diffusion network, like those found in AI image generators. As the joint blog post by DeepMind and Isomorphic Labs announcing AlphaFold 3 explains, it “starts with a cloud of atoms, and over many steps converges on its final, most accurate molecular structure.”

“The holy grail of drug discovery is not just knowing the protein structure, which is what AlphaFold 2 did, but actually designing drug compounds called ligands that bind to the protein’s surface,” Hassabis said. “And you want to know where it binds, and how strongly it binds, in order for you to design the right kind of drug compound. So, AlphaFold 3 is a big step in that direction of predicting protein-ligand binding and how that interaction will work.”

In January this year, Isomorphic Labs announced a strategic partnership with pharmaceutical giants Eli Lilly and Novartis, worth a combined value of around $3 billion. But what’s incredible here is the drug production timeline that’s expected to result from these partnerships.

“So, we’re already working on real drug programs,” said Hassabis. “And I would be expecting maybe in the next couple of years the first AI-designed drugs [appearing] in the clinic.”

"If you ask me the number one thing AI could do for humanity," he continued, "it would be to solve, you know, hundreds of terrible diseases. I can't imagine a better use case for AI. So that's partly the motivation behind Isomorphic and AlphaFold and all the work we do in science, it's to advance society in these big ways."

The full interview between Hassabis and Mackenzie can be viewed in the video.

When it was tested, AlphaFold 3 demonstrated state-of-the-art accuracy in predicting drug-like interactions, including proteins bound with ligands and antibodies bound with target proteins.

Using the PoseBusters benchmark, it was found to be 50% more accurate than the best existing methods – without the need to input any structural information. PoseBusters checks the chemical and physical plausibility of molecular and protein-ligand ‘poses’ generated by a deep-learning model.

And you can play with it yourself. AlphaFold 3 is available via the AlphaFold Server, which includes a database of 200 million protein structures. This phenomenal resource is free to scientists conducting non-commercial research – or indeed just curious Web users worldwide.

Predicting protein structures without a tool like this can take... Well, about as long as it takes to complete a PhD, and can cost hundreds of thousands of dollars. Much like how DeepMind's GNoME tool has catapulted materials and crystals discovery hundreds of years into the future, AlphaFold 3 promises to radically accelerate vast areas in biological science and pharma.

“This new window on the molecules of life reveals how they’re all connected and helps understand how those connections affect biological functions – such as the actions of drugs, the production of hormones and the health-preserving process of DNA repair,” said Google DeepMind and Isomorphic Labs. “This leap could unlock more transformative science, from developing biorenewable materials and more resilient crops, to accelerating drug design and genomics research.”

Research into the predictive capabilities of AlphaFold 3 was published in Nature.

Sources: Google DeepMind, Isomorphic Labs

FAQ

Why does this matter?

AI is slowly starting to understand how life "works" and how to create and manipulate lifes molecules, including DNA, to create new drug treatments, organisms, proteins, and even humans ...

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Sources and further reading

  1. Understanding the faulty proteins linked to cancer and autism deepmind.google
  2. Stopping malaria in its tracks deepmind.google
  3. Creating plastic eating enzymes that could save us from pollution deepmind.google
  4. S41586 021 03819 2 nature.com
  5. Alphafold 2 is here whats behind the structure prediction miracle blopig.com
  6. Deepmind ai crystals newatlas.com
  7. Alphabet ai isomorphic labs drug discovery start newatlas.com
  8. Isomorphic inks deals with eli lilly and novartis for drug discovery techcrunch.com
  9. About golgi.sandbox.google.com
  10. S41586 024 07487 w nature.com
  11. Google deepmind isomorphic alphafold 3 ai model blog.google
  12. Rational drug design with alphafold 3 isomorphiclabs.com

Source: first published by the 311 Institute on 19 June 2024. Cite as: Griffin, M. (2024). DeepMind AI Alphafold 3 finally masters all lifes molecules. 311 Institute. https://www.311institute.com/deepmind-ai-alphafold-3-finally-masters-all-lifes-molecules/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote